MINNEAPOLIS, June 9, 2020 /PRNewswire/ -- Bio-Techne
Corporation (NASDAQ:TECH) is at the forefront of coronavirus
disease 2019 (COVID-19) and SARS-CoV-2 research. This is evidenced
by the large number of published research papers on the subject
that have cited Bio-Techne products, including the breakthrough
Cell paper by Hoffmann et al., which used the R&D
Systems™-branded Anti-Human ACE-2 Antibody to
demonstrate that SARS-CoV-2 uses ACE-2 as a cell entry receptor.
Additionally, the ProteinSimple™-branded
Ella™, an automated immunoassay platform, and its
COVID-19 Cytokine Storm Panel are being used by the Human Immune
Monitoring Center at Mt. Sinai in
New York City to monitor the
immunological response in real time during COVID-19. Today, the
company announced its ongoing efforts to develop new SARS-CoV-2 and
COVID-19 research tools that will provide support for virus
analysis and identification, and the production of therapies and
vaccines. "With multiple brands and thousands of products in our
portfolio tailored to the study and diagnosis of diseases, we are
uniquely positioned to propel the understanding of SARS-CoV-2
pathogenesis and assist in developing COVID-19 treatments,"
commented Kim Kelderman, President
of Bio-Techne's Diagnostics and Genomics Segment.
Bio-Techne's Advanced Cell Diagnostics (ACD) brand has developed
new RNAscope™ probes for the COVID-19 coronavirus.
Several of these probes have already been cited in high impact
publications by Chandrashekar et al., Liu et al.,
Puelles et al., and Patane et al. The RNAscope
platform is an advanced in situ hybridization
assay that enables visualization of single-molecule gene expression
with single-cell resolution directly in intact tissues. These new
probes will allow researchers to visualize and estimate the viral
load in any tissue and cell with morphological context.
Bio-Techne's ACD brand also offers probes for ACE-2, TMPRSS2, and
Cathepsin B and L for identifying cell types that may be vulnerable
to SARS-CoV-2 infection. The RNAscope probes can also be used in
combination with immunohistochemistry-validated antibodies from the
R&D Systems and Novus Biologicals brands to detect viral and
host cell proteins. Accordingly, RNAscope and the Novus
Biologicals™-branded Anti-SARS-Nucleoprotein Antibody
were used in a recently published Science paper to detect
virus-infected cells in lung parenchyma of SARS-CoV-2- infected
Rhesus macaques.
Bio-Techne also offers innovative tools that will help drive the
development of vaccines and therapies for COVID-19. Scientists are
utilizing two avenues for developing COVID-19 treatments: the
creation of new COVID-19 vaccines and the repurposing of existing
drugs. There is an urgent need to create a vaccine to prevent
COVID-19 as it is believed to be the best hope for ending the
pandemic. Bio-Techne's ProteinSimple™-branded Simple
Western™ systems, which are routinely employed in
vaccine development, will be key for developing and manufacturing a
SARS-CoV-2 vaccine. The Simple Western system is the only gel-free,
blot-free, hands-free capillary-based immunoassay platform on the
market. During vaccine development, this platform can be used for
antigen-down serological assays, characterizing proteins as part of
a vaccine, monitoring vaccine component expression, and
quantitating vaccine contamination. In addition, Bio-Techne's
R&D Systems and Novus Biologicals brands are continually
releasing new SARS-CoV-2-related recombinant proteins that can
support binding and drug development studies.
Scientists are also investigating the possibility of using
existing drugs to treat COVID-19, as that strategy could offer a
faster timeline for managing COVID-19. Bio-Techne's Tocris brand
has numerous small molecules that have the potential to be
repurposed for COVID-19 therapeutics research. Additionally, Tocris
has now released a new Tocriscreen™ library of 190
FDA-approved drugs that is ideal for in vitro and in
vivo drug repurposing/repositioning studies. Dave Eansor, President of Bio-Techne's Protein
Sciences Segment commented, "COVID-19 research and drug development
is progressing at an unprecedented pace as the scientific community
searches for a cure. Bio-Techne is continually expanding its
portfolio in order to provide scientists with the critical tools
they need."
The complete portfolio of products for SARS-CoV-2 and COVID-19
research from all the Bio-Techne brands can be found on the R&D
Systems website.
Researchers at Arkana labs used the RNAscope 2.5 HD Brown assay
to visualize SARS-CoV-2 spike protein RNA in the placental tissue
of a COVID-19 positive patient in the second trimester to further
support studies that distinguish the physiological effects of
pre-eclampsia and COVID-19 for better prognosis of infected
pregnant women.
About Bio-Techne Corporation (NASDAQ:TECH)
Contact: David Clair, Senior
Director, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download
multimedia:http://www.prnewswire.com/news-releases/bio-techne-continues-to-expand-its-portfolio-to-support-sars-cov-2-and-covid-19-research-and-therapeutic-development-301072130.html
SOURCE Bio-Techne Corporation